Practical guide to the use of chemotherapy in castration resistant prostate cancer.

摘要: Introduction Chemotherapy, once thought to be toxic and ineffective in men with castration resistant prostate cancer (CRPC), has a significant impact on survival quality-of-life these patients. This article summarizes recent studies performed two Food Drug Administration (FDA) approved agents which have improved CRPC, docetaxel cabazitaxel. Materials methods The literature cytotoxic chemotherapy for was reviewed. individual efficacy, mechanisms of chemotherapeutic action, appropriate disease states administration were identified. Recent clinical trial results combined targeted also Results Front line therapy consists prednisone. In randomized trials, based demonstrated 20%-24% improvement over the palliative standard care, mitoxantrone Eight trials combining docetaxel/prednisone other antiangiogenic, bone targeted, vaccine or metabolic therapies failed demonstrate an alone. Cabazitaxel, analogue activity taxane cell lines, is by FDA, use CRPC patients who previous exposure docetaxel. Conclusions Docetaxel prednisone remains care as first CRPC. Cabazitaxel effective second agent that improves survival; are underway comparing cabazitaxel chemotherapy. Given its lack benefit, well emergence new treatments cancer, diminished role treatment